Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243764 | 0.89 | ALOX5AP (0.53) | AOC3NPC1RAB9AMAOBSMN1; SMN2 | |
| SCHEMBL2997565 | 0.88 | NPC1 (0.50) | AOC3NPC1RAB9AMAOBSMN1; SMN2 | |
| SCHEMBL2993029 | 0.88 | NPC1 (0.52) | NPC1RAB9AMAOBSMN1; SMN2RECQL | |
| SCHEMBL3000148 | 0.84 | AOC3 (0.41) | AOC3NPC1RAB9AMAOBSMN1; SMN2 | |
| SCHEMBL2997742 | 0.82 | NPC1 (0.36) | NPC1RAB9AMAOBSMN1; SMN2LMNA | |
| SCHEMBL13248368 | 0.82 | NPC1 (0.36) | NPC1RAB9AMAOBSMN1; SMN2LMNA | |
| SCHEMBL3000422 | 0.82 | NPC1 (0.36) | NPC1RAB9AMAOBSMN1; SMN2LMNA | |
| SCHEMBL2245990 | 0.77 | ALOX5AP (0.54) | NPC1RAB9AMAOBSMN1; SMN2LMNA | |
| SCHEMBL3000768 | 0.76 | MAOB (0.43) | RAB9AMAOBALOX5AP | |
| SCHEMBL2988798 | 0.75 | LMNA (0.41) | AOC3NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | AOC3 497/4885NPC1 603/4885RAB9A 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.